• Small-Molecule Inhibition of uPAR·uPA Blocks Cancer Cell Inv

  2026-06-16

  Khanna et al. present the discovery of small molecules that directly inhibit the high-affinity interaction between urokinase receptor (uPAR) and uPA, a critical driver of tumor invasion and metastasis. By leveraging virtual screening across multiple uPAR conformations, they identify and validate compounds like IPR-803, which block cell invasion without broadly impairing migration or adhesion, offering precision tools for dissecting metastatic mechanisms.

• Cyclopamine as a Hedgehog Signaling Inhibitor in Cancer Rese

  2026-06-16

  Cyclopamine stands out as a precise Hedgehog signaling inhibitor, enabling targeted exploration of cancer pathways and developmental biology. Its robust anti-proliferative and apoptosis-inducing effects, paired with practical workflow compatibility, make it indispensable for both in vitro and in vivo research.

• Host CK2α–VP2 Interaction as an Antiviral Target in CIAV Rep

  2026-06-15

  This study uncovers that chicken infectious anemia virus (CIAV) depends critically on direct interaction between its VP2 protein and host CK2α for efficient replication and pathogenesis. Disrupting this interaction, either by CK2α inhibition or targeted VP2 mutagenesis, suppresses viral growth, highlighting CK2α as a promising antiviral target.

• NF449 as a Selective P2X1 Antagonist: Implications for Plate

  2026-06-15

  The reference study establishes NF449 as a highly selective antagonist of the platelet P2X1 receptor, demonstrating its ability to inhibit platelet activation and aggregation in vitro and in vivo without significantly affecting hemostasis. These findings elucidate the distinct roles of P2 receptor subtypes in thrombus formation and guide the design of targeted antithrombotic strategies.

• Dabigatran Etexilate: Clinical Advances in Oral Thrombin Inh

  2026-06-14

  Dabigatran etexilate introduces a paradigm shift as the first oral direct thrombin inhibitor for stroke and venous thromboembolism prevention, offering predictable anticoagulation without the need for routine monitoring. This review outlines its pharmacological innovation, efficacy, and practical implications for anticoagulant research.

• Resiniferatoxin (RTX): Translating TRPV1 Science Into Analge

  2026-06-13

  Explore how Resiniferatoxin (RTX), an ultra-potent TRPV1 agonist, is reshaping pain research and translational workflows by targeting sensory neuron desensitization. This article blends mechanistic insights, experimental evidence, and strategic guidance for researchers navigating the evolving landscape of osteoarthritis and neuropathic pain innovation.

• Deuterated Azole CYP51 Inhibitors: Innovations Against IFIs

  2026-06-12

  This study introduces deuterated diphenyl azole alcohol-based CYP51 inhibitors, designed via molecular hybridization using Oteseconazole and A33 as structural references. The research demonstrates that compound C52 achieves high oral bioavailability and broad-spectrum antifungal activity, including efficacy against drug-resistant Candida, providing a new framework for next-generation antifungal agents.

• Polybrene (Hexadimethrine Bromide) for Viral Transduction Wo

  2026-06-12

  Polybrene (Hexadimethrine Bromide) 10 mg/mL remains the gold-standard reagent for boosting viral gene transduction and lipid-mediated DNA delivery, especially in challenging cell types. This article details optimized experimental setups, workflow enhancements, and troubleshooting strategies that maximize reproducibility and efficiency in applications spanning gene therapy, erythrocyte assays, and peptide sequencing.

• Trelagliptin Succinate Enhances Insulin Sensitivity via PI-3

  2026-06-11

  The reference study demonstrates that trelagliptin succinate, a DPP-4 inhibitor, improves insulin resistance in adipocytes by activating the PI-3K/AKT/GLUT4 signaling axis and reducing adverse adipokine secretion. These insights clarify trelagliptin's molecular mechanism and guide future research on phosphorylation-dependent insulin signaling.

• Estradiol–Autophagy Axis: Organ Protection in Perimenopausal

  2026-06-11

  This study uncovers how declining estradiol in perimenopause increases risk for cardiovascular, renal, and metabolic disorders by impairing autophagy via estrogen receptor signaling. Integrating human cohort data, network pharmacology, and mouse models, the research establishes that estrogen receptor–mediated autophagy is central to the tissue-protective effects of 17 beta-estradiol, suggesting new directions for precision hormone therapy and translational modeling.

• HyperTrap Heparin HP Column: Resolving Stemness Pathways wit

  2026-06-10

  Explore how the HyperTrap Heparin HP Column empowers researchers to dissect CCR7–Notch1 stemness signaling by enabling ultra-high-resolution purification of regulatory proteins. This article reveals advanced protocol guidance and practical assay insights that set it apart from existing content.

• Deep Learning Reveals Cardiotoxicity in iPSC-CMs Screening

  2026-06-10

  Grafton et al. introduced a scalable deep learning approach for detecting drug-induced cardiotoxicity using high-content imaging of human iPSC-derived cardiomyocytes. This method enables early identification of cardiotoxic compounds and chemical frameworks, improving preclinical safety assessment in drug discovery.

• Cisapride (R 51619) in Cardiac Electrophysiology Research

  2026-06-09

  Cisapride (R 51619) is a dual-action probe pivotal for dissecting 5-HT4 receptor signaling and hERG channel inhibition, enabling robust phenotypic screening in cardiac arrhythmia research. Learn how its use transforms experimental workflows, from iPSC-cardiomyocyte models to high-content cardiotoxicity detection, with practical troubleshooting strategies for optimal data fidelity.

• Astrocytic GAT-3 Controls DG Synaptic Transmission and Memor

  2026-06-09

  This study uncovers how astrocytic GAT-3 modulates synaptic transmission and memory formation in the dentate gyrus by linking GABA transporter activity to Ca2+-dependent astrocyte signaling. The findings highlight a crucial glial mechanism underpinning hippocampal plasticity, advancing our understanding of cognitive regulation and pointing to novel targets for intervention.

• Genomic Instability Drives Therapeutic Heterogeneity in CRC

  2026-06-08

  This study by Cho et al. dissects how dynamic genomic and transcriptomic alterations during colorectal cancer metastasis underlie heterogeneous responses to therapy. Using patient-derived xenograft models and multi-omics profiling, the research uncovers subclonal evolution and its implications for drug resistance and treatment outcomes.

16228 records 1/1082 page Next 12345 下5页 Last page